BSX
Boston Scientific Corporation
Price performance
Sep 18, 2026About
Company activity
43 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 09/08 | BSX | 8-K | Boston Scientific Discloses Material Cybersecurity Incident Impacting Operations | — | — | — |
| 08/26 | BSX | 8-K | Boston Scientific Discloses Cybersecurity Incident | — | — | — |
| 07/29 | BSX | 8-K | Boston Scientific Reports Strong Q2 2026 Financial Results and Strategic Investments | — | — | — |
| 07/27 | BSX | 8-K | Boston Scientific Announces New Global Restructuring Plan | — | — | — |
| 05/18 | BSX | 8-K | Boston Scientific Announces $2 Billion Accelerated Share Repurchase Agreement | — | — | — |
| 05/18 | BSX | 8-K | Boston Scientific Invests $1.5 Billion in MiRus LLC for TAVR System Access | — | — | — |
| 05/05 | BSX | 8-K | Boston Scientific Amends Corporate Charter at 2026 Annual Meeting | — | — | — |
| 04/22 | BSX | 8-K | Boston Scientific Reports Strong Q1 2026 Results and Raises Guidance | — | — | — |
| 03/30 | BSX | 8-K | Boston Scientific's EKOS System Demonstrates Superiority in Treating Acute Pulmonary Embolism | — | — | — |
| 02/26 | BSX | 8-K | Boston Scientific Enters New Revolving Credit Agreement | — | — | — |
| 02/23 | BSX | 8-K | Boston Scientific Appoints New Directors and Increases Stock Repurchase Authorization | — | — | — |
| 02/05 | BSX | 8-K | Board Member Yoshiaki Fujimori to Depart Boston Scientific | — | — | — |
| 02/04 | BSX | 8-K | Boston Scientific Reports Strong 2025 Financial Results | — | — | — |
| 01/15 | BSX | 8-K | Boston Scientific Announces Acquisition of Penumbra, Inc. | — | — | — |
| 01/15 | BSX | 8-K | Boston Scientific Announces Merger Agreement with Penumbra | — | — | — |
| 11/19/25 | BSX | 8-K | Boston Scientific Corporation Approves 2026 Annual Bonus and Performance Share Programs | — | — | — |
| 10/23/25 | BSX | 8-K | Boston Scientific Director to Depart in 2026 | — | — | — |
| 10/22/25 | BSX | 8-K | Boston Scientific Announces Strong Third Quarter 2025 Results | — | — | — |
| 09/04/25 | BSX | 8-K | Boston Scientific Announces Retirement of EVP and President of Peripheral Interventions | — | — | — |
| 07/23/25 | BSX | 8-K | Boston Scientific Reports Strong Q2 2025 Results with Beating Guidance and Acquisitions | — | — | — |
| 05/28/25 | BSX | 8-K | Boston Scientific Discontinues ACURATE Valve Systems Sales Globally | — | — | — |
| 05/06/25 | BSX | 8-K | Boston Scientific Shareholders Approve Key Proposals at 2025 Annual Meeting | — | — | — |
| 04/23/25 | BSX | 8-K | Boston Scientific Reports Strong First Quarter 2025 Financial Results | — | — | — |
| 04/23/25 | BSX | 8-K | Boston Scientific Announces CFO Retirement and Succession Plan | — | — | — |
| 02/26/25 | BSX | 8-K | Boston Scientific Announces Senior Notes Offering | — | — | — |
| 02/12/25 | BSX | 8-K | Board Member Departure Announced by Boston Scientific Corporation | — | — | — |
| 02/05/25 | BSX | 8-K | Boston Scientific Reports Strong Q4 and Full Year 2024 Results and Provides 2025 Guidance | — | — | — |
| 01/16/25 | BSX | 8-K | Boston Scientific Granted Preliminary Approval for Settlement | — | — | — |
| 11/22/24 | BSX | 8-K | Boston Scientific Approves 2025 Compensation Programs | — | — | — |
| 11/15/24 | BSX | 8-K | Boston Scientific Completes Acquisition of Axonics, Inc. | — | — | — |
| 11/07/24 | BSX | 8-K | Boston Scientific Resumes AVANT GUARD Clinical Trial for New Patient Population | — | — | — |
| 10/23/24 | BSX | 8-K | Boston Scientific Reports Strong Q3 2024 Earnings, Announces Strategic Developments | — | — | — |
| 07/30/24 | BSX | 8-K | Boston Scientific Appoints New Director | — | — | — |
| 07/24/24 | BSX | 8-K | Boston Scientific Reports Strong Q2 2024 Financial Results and Business Developments | — | — | — |
| 05/10/24 | BSX | 8-K | Boston Scientific Appoints Dr. Cheryl Pegus to Board of Directors | — | — | — |
| 05/06/24 | BSX | 8-K | Boston Scientific Updates By-Laws and Holds Annual Meeting | — | — | — |
| 04/24/24 | BSX | 8-K | Boston Scientific Announces Strong Q1 2024 Financial Results | — | — | — |
| 04/04/24 | BSX | 8-K | Boston Scientific's Merger with Axonics Receives Second Request from FTC | — | — | — |
| 02/27/24 | BSX | 8-K | Boston Scientific Prices €2.0 Billion Senior Notes Offering | — | — | — |
| 01/31/24 | BSX | 8-K | Boston Scientific Reports Strong Q4 and FY 2023 Results, Exceeds Guidance | — | — | — |
| 01/31/24 | BSX | 8-K | Boston Scientific Appoints New Chief Accounting Officer | — | — | — |
| 01/08/24 | BSX | 8-K | Boston Scientific Announces Agreement to Acquire Axonics, Inc. | — | — | — |
| 01/08/24 | BSX | 8-K | Boston Scientific Announces Merger with Axonics | — | — | — |
BSX filing record
Boston Scientific Corporation (BSX): 43 8-K filings summarized, the most recent on Sep 8, 2026.
What the 8-K filings said
- Sep 8, 2026 · high impact
Boston Scientific Corporation disclosed a material cybersecurity incident on August 25, 2026, which affected its information technology systems and led to a global disruption in operations. The incident involved unauthorized activity on certain systems, causing a network outage that impacted manufacturing and order…
Boston Scientific Discloses Material Cybersecurity Incident Impacting Operations - Aug 26, 2026 · high impact
On August 25, 2026, Boston Scientific Corporation identified a cybersecurity incident affecting its information technology systems, leading to global disruptions in its operations. The company has activated its incident response protocols and is working with third-party cybersecurity experts to investigate and contain…
Boston Scientific Discloses Cybersecurity Incident - Jul 29, 2026 · medium impact
Boston Scientific Corporation announced strong financial results for the second quarter of 2026, with net sales of $5.442 billion, a 7.5% increase on a reported basis and 7.0% on an organic basis compared to the prior year. The company reported GAAP net income of $907 million or $0.61 per share, and adjusted EPS of…
Boston Scientific Reports Strong Q2 2026 Financial Results and Strategic Investments - Jul 27, 2026 · medium impact
On July 21, 2026, Boston Scientific Corporation announced a new global restructuring program, the 2026 Restructuring Plan, aimed at driving sustained cost efficiencies and enabling continued growth. The plan is expected to result in total pre-tax charges of approximately $700 million to $800 million, with…
Boston Scientific Announces New Global Restructuring Plan - May 18, 2026 · medium impact
On May 18, 2026, Boston Scientific Corporation announced an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association for $2 billion of its common stock. This ASR is part of the company's previously announced $5 billion share repurchase authorization. Under the terms of the ASR…
Boston Scientific Announces $2 Billion Accelerated Share Repurchase Agreement
SEC filings in the last five years
- 60 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K
- 1 Form 10-K/A